Key clinical point: Suboptimal adherence to oral anticancer (OAC) agents was observed among patients with chronic myeloid leukemia (CML), highlighting the need for implementation of personalized counseling to address the risk for nonadherence and enhance treatment outcomes.
Major finding: Almost 17.9% of participants reported nonadherence, i.e., missing at least 1 dose of CML medication in the previous week. Patients who missed at least 1 vs. 0 doses in the last 7 days reported that medication was somewhat to very hard to take (50.0% vs. 18.6%; P = .008) or they missed doses because of side effects (50.0% vs. 11.4%; P = .001) or busy schedule (37.5% vs. 2.9%; P = .004).
Study details: This study included 86 adult patients with CML with a prescription of OAC agents (imatinib, nilotinib, dasatinib, bosutinib, or ponatinib) for at least 30 days.
Disclosures: This study was funded by grants from the National Cancer Institute and partly by the Institute of General Medical Sciences of the National Institutes of Health. The authors declared no conflict of interests.
Source: Davis TC et al. Int J Environ Res Public Health. 2021;18(21):11045 (Oct 21). Doi: 10.3390/ijerph182111045.